Recombinant Human IGHA1 Protein: Researcher's Guidelines

Recombinant Human IGHA1 Protein is a research-grade recombinant form of the human immunoglobulin heavy constant alpha 1 chain, designed to support immunology assays, antibody research, and related in vitro experimental workflows.

Product Name

Recombinant Human IGHA1 Protein

SKU

rp367891

Protein Origin

Human (Homo sapiens) IGHA1 gene-derived recombinant protein

Primary Application

Immunology research, IgA pathway studies, in vitro binding and functional assays

Storage Recommendation

Store at -20°C or -80°C; avoid repeated freeze-thaw cycles

Regulatory Status

For research use only (RUO); not for diagnostic or therapeutic use

Biological Background of IGHA1

Immunoglobulin Heavy Constant Alpha 1 (IGHA1) encodes the constant region of the immunoglobulin alpha 1 heavy chain, a key structural component of Immunoglobulin A (IgA). IgA is the predominant antibody class found at mucosal surfaces and in secretions such as saliva, tears, colostrum, and intestinal fluid, playing an essential role in mucosal immunity and first-line defense against pathogens.

The IGHA1 gene is located in the immunoglobulin heavy chain locus on chromosome 14 in humans. The encoded protein constitutes the heavy chain of IgA1, one of the two IgA subclasses (IgA1 and IgA2). IgA1 predominates in serum and is characterized by an extended hinge region relative to IgA2, which influences its susceptibility to bacterial IgA proteases and its interaction with Fc alpha receptors (FcαRI/CD89).

Recombinant Human IGHA1 Protein provides researchers with a well-defined, consistently produced reagent for studying IgA-mediated immune mechanisms, receptor binding, and mucosal immune responses without the batch variability associated with plasma-derived IgA.

Product Specifications and Quality Attributes

Recombinant Human IGHA1 Protein (SKU: rp367891) is produced using recombinant DNA technology. Key specifications researchers should verify upon receipt include purity, host expression system, molecular weight, and endotoxin levels. Please consult the Certificate of Analysis (CoA) supplied with each lot for confirmed values, as these may vary between production lots.

• Expression System: Typically mammalian or prokaryotic expression systems are used for recombinant immunoglobulin fragments; refer to the product datasheet for the specific system used for rp367891.
• Purity: Research-grade recombinant proteins are typically >85–95% purity as assessed by SDS-PAGE or HPLC; confirm exact purity from CoA.
• Endotoxin Level: Endotoxin content should be confirmed from the CoA; low endotoxin preparations are preferred for cell-based assays.
• Formulation: Supplied in a stabilizing buffer; refer to the product datasheet for exact buffer composition, protein concentration, and any carrier proteins present (e.g., BSA).

All lot-specific numerical values (purity %, endotoxin EU/mg, molecular weight confirmation) should be verified against the CoA provided at time of shipment.

Reconstitution, Handling, and Storage Protocol

Proper handling of Recombinant Human IGHA1 Protein is critical to maintaining its biological activity and structural integrity. Follow these guidelines carefully:

1. Reconstitution: If supplied lyophilized, allow the vial to equilibrate to room temperature for 10–15 minutes before opening. Reconstitute in sterile, ultrapure water or the buffer recommended in the product datasheet to the target concentration. Mix gently by pipetting or slow vortexing; do not vigorously vortex.
2. Centrifugation: Briefly centrifuge the vial before opening to collect any residual material from the cap or walls.
3. Aliquoting: Prepare single-use aliquots immediately after reconstitution to avoid repeated freeze-thaw cycles, which degrade protein activity.
4. Storage Conditions: Store long-term at -80°C. For short-term use (up to 1 week), -20°C is acceptable. Avoid storage at 4°C for extended periods. Do not expose to repeated freeze-thaw cycles (limit to ≤3 cycles).
5. Sterile Technique: Use sterile consumables and work under aseptic conditions, particularly if the protein is intended for cell culture experiments.

Note: Specific reconstitution volume and recommended working concentration should be taken from the product datasheet for rp367891. The above steps represent general best-practice guidance for recombinant proteins.

Experimental Applications

Recombinant Human IGHA1 Protein is suitable for a range of research applications in immunology, biochemistry, and mucosal biology. Representative applications include:

• ELISA and Immunoassays: Use as a standard or capture/detection antigen in enzyme-linked immunosorbent assays to quantify IgA or study anti-IgA antibody responses.
• Binding and Interaction Studies: Investigate interactions between IgA1 heavy chain and Fc receptors (e.g., FcαRI/CD89), polymeric immunoglobulin receptor (pIgR), or bacterial virulence factors such as IgA proteases.
• Cell-Based Functional Assays: Examine IgA-mediated effector functions including antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and neutrophil activation in vitro.
• Structural and Biophysical Studies: Employ in surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or crystallography studies to characterize IgA1 heavy chain interactions.
• Positive Control: Serve as a reference standard or positive control in Western blotting, dot blot, and immunoprecipitation experiments involving IgA1.

Always titrate the protein for each specific assay format and biological system to determine optimal working concentrations.

Troubleshooting Common Issues

Researchers may encounter the following issues when working with Recombinant Human IGHA1 Protein. The guidance below reflects general best practice for recombinant proteins:

Issue	Likely Cause	Recommended Action
Low or no signal in ELISA	Suboptimal coating concentration or protein denaturation	Optimize coating concentration; check protein integrity by SDS-PAGE; ensure correct storage history
Protein aggregation	Improper reconstitution or freeze-thaw damage	Reconstitute at recommended concentration; use single-use aliquots; centrifuge at 10,000 × g for 10 min before use to remove aggregates
Unexpected molecular weight band on SDS-PAGE	Glycosylation heterogeneity or incomplete denaturation	Confirm expected molecular weight from datasheet; use reducing conditions; consult CoA for expected band pattern
Cytotoxicity in cell-based assays	Elevated endotoxin or carrier protein sensitivity	Confirm endotoxin levels from CoA; select endotoxin-tested lot; use BSA-free formulation if cells are BSA-sensitive

Frequently asked questions

What is the biological function of IGHA1 and why is it relevant to research?

IGHA1 encodes the heavy chain constant region of IgA1, the predominant serum IgA subclass. IgA1 plays central roles in mucosal immunity, pathogen neutralization, and Fc receptor-mediated effector functions. Studying IGHA1 is relevant for mucosal immunology, autoimmune disease research (e.g., IgA nephropathy), vaccine development, and understanding host-pathogen interactions at mucosal surfaces.

How should I determine the optimal working concentration of rp367891 for my assay?

The optimal working concentration varies depending on the assay format, detection method, and biological system used. It is recommended to perform a titration experiment using a range of concentrations (e.g., 0.1–10 µg/mL for ELISA applications) and select the concentration yielding the best signal-to-noise ratio. Consult the product datasheet for any application-specific guidance provided by Aladdin Scientific.

How many freeze-thaw cycles can rp367891 withstand without significant loss of activity?

As a general guideline for recombinant proteins, it is recommended to limit freeze-thaw cycles to no more than three. Repeated freeze-thaw cycles can cause protein aggregation, denaturation, and loss of functional activity. Single-use aliquoting immediately after reconstitution is the best strategy to preserve protein integrity over time.

Is Recombinant Human IGHA1 Protein suitable for in vivo or clinical use?

No. Recombinant Human IGHA1 Protein (rp367891) is designated for research use only (RUO) and is not approved, validated, or intended for diagnostic, therapeutic, or clinical applications. Researchers must not use this product in human subjects or for any clinical purpose.

What expression system is used to produce rp367891, and does it affect glycosylation?

The specific expression system for rp367891 should be confirmed in the product datasheet. Different expression systems (mammalian, insect, or prokaryotic) produce proteins with different glycosylation profiles. Mammalian expression systems typically yield human-like glycosylation, while prokaryotic systems produce non-glycosylated protein. Researchers studying IgA1 glycan-dependent functions should confirm the glycosylation status from the product datasheet or by contacting Aladdin Scientific technical support.

References

1. Woof JM, Kerr MA. The function of immunoglobulin A in immunity. Journal of Pathology. 2006;208(2):270–282. doi:10.1002/path.1877
2. Mestecky J, Russell MW, Elson CO. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut. 1999;44(1):2–5. doi:10.1136/gut.44.1.2
3. Monteiro RC, Van De Winkel JG. IgA Fc receptors. Annual Review of Immunology. 2003;21:177–204. doi:10.1146/annurev.immunol.21.120601.141011

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.